Esperion price target raised to $5 from $4 at Citizens

Citizens raised the firm’s price target on Esperion (ESPR) to $5 from $4 and keeps an Outperform rating on the shares. Esperion reported Q4 results consistent with the preannouncement in January and continues to execute its Vision 2040 plans underscored by the recent acquisition of Corstasis Therapeutics and ongoing pipeline expansion through advancement of ESP-2001, the analyst tells investors in a research note.